{
  "id": 11935930,
  "title": "Forget Zepbound: Eli Lilly's Next Weight-Loss Drug Could Be Its Biggest Blockbuster Yet",
  "url": "https://urgent.news/2026/10/04/forget-zepbound-eli-lillys-next-weight-loss-drug-could-be-its-biggest",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-04T13:15:01.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/10/04/forget-zepbound-eli-lilly-s-next-weight-loss-drug-could-be-its-biggest-blockbuster-yet/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Eli Lilly, the biggest player in the healthcare sector, has seen impressive returns on its investment in the anti-obesity market. Its lead product, Zepbound, has been a standout performer, boasting exceptional sales growth. However, the company has a number of promising pipeline drugs, one of which may surpass Zepbound in performance. Zepbound's unique selling point is its dual action on GLP-1 and GIP gut hormones, a strategy that has yielded superior weight loss results compared to its main rival, Wegovy, which only stimulates GLP-1.",
  "summary": "Can anyone stop Eli Lilly’s progress in the weight loss market?",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Forget Zepbound: Eli Lilly's Next Weight-Loss Drug Could Be Its Biggest Blockbuster Yet",
        "url": "https://urgent.news/2026/10/04/forget-zepbound-eli-lillys-next-weight-loss-drug-could-be-its-biggest-11936982",
        "published": "2026-10-04T13:35:01.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}